Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiora Pharmaceuticals (KPRX) Other Non-Current Assets (2016 - 2025)

Kiora Pharmaceuticals (KPRX) has disclosed Other Non-Current Assets for 11 consecutive years, with $61007.0 as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Other Non-Current Assets rose 89.92% year-over-year to $61007.0, compared with a TTM value of $61007.0 through Jun 2025, up 89.92%, and an annual FY2024 reading of $4057.0, down 5.65% over the prior year.
  • Other Non-Current Assets was $61007.0 for Q2 2025 at Kiora Pharmaceuticals, up from $4057.0 in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $61007.0 in Q2 2025 and bottomed at $4031.0 in Q3 2023.
  • Average Other Non-Current Assets over 5 years is $34351.1, with a median of $44249.0 recorded in 2021.
  • The sharpest move saw Other Non-Current Assets crashed 91.78% in 2023, then surged 674.02% in 2024.
  • Year by year, Other Non-Current Assets stood at $45000.0 in 2021, then increased by 8.97% to $49037.0 in 2022, then tumbled by 91.23% to $4300.0 in 2023, then fell by 5.65% to $4057.0 in 2024, then surged by 1403.75% to $61007.0 in 2025.
  • Business Quant data shows Other Non-Current Assets for KPRX at $61007.0 in Q2 2025, $4057.0 in Q4 2024, and $29851.0 in Q3 2024.